Trial Profile
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Apr 2020
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 16 Jan 2018 Status changed from not yet recruiting to completed.
- 04 Nov 2017 New trial record